Agilent, Waters Face Diverging Outlooks on Growth and Integration Risks, Morgan Stanley Says

MT Newswires Live12-03

Agilent Technologies (A) and Waters (WAT) are facing differing outlooks based on end-market exposure, product cycles and integration risks, Morgan Stanley said in a note Tuesday.

The firm initiated Agilent at overweight and Waters at equal-weight.

Morgan Stanley analysts said Agilent is positioned for long-term EPS growth following recently implemented strategic and organizational changes are expected to support stronger revenue and margin expansion.

Agilent's price target is at $180 per share.

For Waters, Morgan Stanley said it sees "clear signs of progress" in the company's core analytical instrument business but is awaiting more visibility into its integration of Becton Dickinson's biosciences and diagnostic assets.

The firm also said the size and profiles of the acquired businesses introduce near-term uncertainty despite longer-term synergy potential.

Morgan Stanley pegged the company's price target at $423 per share.

Price: 150.67, Change: +0.57, Percent Change: +0.38

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment